The text starts here.

BELVIQ®
lorcaserin HCI

The Drug Enforcement Agency (DEA) has placed BELVIQ into Schedule IV of the Controlled Substances Act with an effective date of June 7, 2013.

For more information about BELVIQ, please read the full prescribing information.

 

 

 

 

 

 

 

 

 

The health information contained herein is provided for educational purposes only and is not intended to replace discussions with a health care provider. All decisions regarding patient care must be made with a health care professional, considering the unique characteristics of the patient.

 

This site is intended for residents of the United States only. The products discussed herein may have different product labeling in different countries.

 

This Web site contains information relating to various medical conditions and treatment. Such information is provided for educational purposes only and is not meant to be a substitute for the advice of a physician or other health care professionals. You should not use this information for diagnosing a health problem or disease. In order for you to make intelligent health care decisions, you should always consult with a physician or other health care provider for you, or your loved ones, personal medical needs. Individual responses to treatment may vary.